Oxytocin and Affect Processing in Posttraumatic Stress Disorder
Posttraumatic Stress Disorder (PTSD)
About this trial
This is an interventional treatment trial for Posttraumatic Stress Disorder (PTSD)
Eligibility Criteria
Inclusion Criteria:
- Adults: age 18-55
- Be in good medical health
- Be cooperative with testing
- English is a language spoken in the family
- PTSD as diagnosed by a certified clinician or the research team for PTSD group.
Exclusion Criteria:
- Moderate or severe acute or chronic medical illnesses (e.g.cardiac disease, diabetes, epilepsy, influenza).
- History of hypertension with baseline blood pressure above 160 mm Hg (systolic) over 100 mm Hg (diastolic).
- history of syncope and/or baseline blood pressure below 100 mm Hg (systolic).
- weight >300lb
- The use of some psychotropic medications will not be allowed. Females taking contraceptive hormones will not be able to participate in the study.
- Currently breast feeding or pregnant
- For MRI ONLY: Any metal or electromagnetic implants
- For MRI ONLY: Significant hearing loss or other severe sensory impairment
- A fragile health status.
- For MRI ONLY: A history of seizures or current use of anticonvulsants
- Healthy adult controls (HC):
- Be free of both neurological and psychiatric disorders (current and past) on the basis of self-report
- Be free of psychiatric disorders
Sites / Locations
- Yale University
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Healthy adult controls (18-55)
Adults with PTSD (18-55)
Trauma-exposed/no-PTSD adults (18-55)
Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).